Effective detection of BRAFV595E mutation in canine urothelial and prostate carcinomas using immunohistochemistry.

Aeschlimann, Leonore; Kehl, Alexandra; Guscetti, Franco; Posthaus, Caroline; Aupperle-Lellbach, Heike; Rottenberg, Sven; De Brot, Simone (2024). Effective detection of BRAFV595E mutation in canine urothelial and prostate carcinomas using immunohistochemistry. Veterinary and comparative oncology, 22(2), pp. 295-302. Wiley 10.1111/vco.12978

Preview

Text Vet_Comparative_Oncology_-_2024_-_Aeschlimann_-_Effective_detection_of_BRAFV595E_mutation_in_canine_urothelial_and_prostate.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview

Canine urothelial carcinoma (UC) and prostate carcinoma (PC) frequently exhibit the BRAFV595E mutation, akin to the BRAFV600E mutation common in various human cancers. Since the initial discovery of the BRAF mutation in canine cancers in 2015, PCR has been the standard method for its detection in both liquid and tissue biopsies. Considering the similarity between the canine BRAFV595E and human BRAFV600E mutations, we hypothesized that immunohistochemistry (IHC) using a BRAFV600E-specific antibody could effectively identify the canine mutant BRAFV595E protein. We tested 122 canine UC (bladder n = 108, urethra n = 14), 21 PC, and benign tissue using IHC and performed digital droplet PCR (ddPCR) on all 122 UC and on 14 IHC positive PC cases. The results from ddPCR and IHC were concordant in 99% (135/136) of the tumours. Using IHC, BRAFV595E was detected in 72/122 (59%) UC and 14/21 (65%) PC. Staining of all benign bladder and prostate tissues was negative. If present, mutant BRAF staining was homogenous, with rare intratumour heterogeneity in three (4%) cases of UC. Additionally, the BRAFV595E mutation was more prevalent in tumours with urothelial morphology, and less common in glandular PC or UC with divergent differentiation. This study establishes that BRAFV600-specific IHC is a reliable and accurate method for detecting the mutant BRAFV595E protein in canine UC and PC. Moreover, the use of IHC, especially with tissue microarrays, provides a cost-efficient test for large-scale screening of canine cancers for the presence of BRAF mutations. This advancement paves the way for further research to define the prognostic and predictive role of this tumour marker in dogs and use IHC to stratify dogs for the treatment with BRAF inhibitors.

Interest & Impact

Downloads

2 since deposited on 29 Apr 2024
2 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item